Sugi Predict

Sugi Predict / Compounds / SCHEMBL3208049

SCHEMBL3208049

SCHEMBL3208049

Cc1ccc(NC(=O)Nc2ccc(C#N)c(CN3CCN(C(=O)O)CC3)c2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 2/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ DDX3X O00571 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ RORC P51449 1/20 0.38
▸ DHODH Q02127 1/20 0.38
▸ KDR P35968 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ RET P07949 1/20 0.37
▸ CCR3 P51677 1/20 0.36
▸ WNT1 P04628 1/20 0.36
▸ CLK2 P49760 1/20 0.36
▸ CLK3 P49761 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ MAPK8 P45983 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399487 0.91 MGLL (0.42) ARMGLLNPSR1DDX3XALDH1A1
SCHEMBL3200744 0.87 MEN1 (0.45) NPSR1DDX3XPOLBALDH1A1CNR2
SCHEMBL3206500 0.85 NPSR1 (0.48) NPSR1DDX3XPOLBALDH1A1NPC1
SCHEMBL3215364 0.85 KCNQ3 (0.45) NPSR1DDX3XPOLBALDH1A1RORC
SCHEMBL3210260 0.81 RORC (0.44) NPSR1DDX3XPOLBALDH1A1RORC
SCHEMBL3198046 0.80 ACKR3 (0.52) POLBNPC1RAB9ASMN1; SMN2CCR3
SCHEMBL3211043 0.79 RORC (0.43) NPSR1DDX3XPOLBALDH1A1RORC
SCHEMBL3209060 0.79 NPSR1 (0.43) NPSR1ALDH1A1RORCDHODHNPC1
SCHEMBL3206886 0.78 RORC (0.61) NPSR1RORCDHODHNPC1RAB9A
SCHEMBL3196401 0.78 NPSR1 (0.43) NPSR1DDX3XALDH1A1RORCDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-9150564-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2015-10-06 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 AR 4824/4885MGLL 3513/4885NPSR1 4262/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 AR 4679/4885MGLL 3999/4885NPSR1 4682/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 AR 4689/4885MGLL 4501/4885NPSR1 4567/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 AR 4679/4885MGLL 3999/4885NPSR1 4682/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 AR 4240/4885MGLL 3974/4885NPSR1 3300/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 AR 4679/4885MGLL 3999/4885NPSR1 4682/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 AR 4699/4885MGLL 4296/4885NPSR1 4780/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 AR 4240/4885MGLL 3974/4885NPSR1 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.